-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OJGIMEx3vcbSOD/bsyfPYK6Hj69p31Y+f17uU3FsllLabggndWWIk51lPqFtrRVt 9AaUAnnVKjpMu/KotdfNZQ== 0000947871-04-001913.txt : 20040809 0000947871-04-001913.hdr.sgml : 20040809 20040806204152 ACCESSION NUMBER: 0000947871-04-001913 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20040809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-95805 FILM NUMBER: 04959304 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2124496202 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 f424b3_080404-pharmaceutical.htm PROSPECTUS SUPPLEMENT
PROSPECTUS SUPPLEMENT
(To Prospectus dated July 7, 2003) 		Filed Pursuant to Rule No. 424(b)(3)
REGISTRATION NO. 333-92161
333-95805

1,000,000,000 Depositary Receipts
Pharmaceutical HOLDRS (SM) Trust

        This prospectus supplement supplements information contained in the prospectus dated July 7, 2003 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS (SM) Trust.

        The share amounts specified in the table in the “Highlights of Pharmaceutical HOLDRS” section of the base prospectus shall be replaced with the following:

Name of Company
 Ticker
 Share
Amounts
 Primary
Trading Market
Abbott Laboratories ABT 14  NYSE
Allergan, Inc. AGN 1  NYSE
Andrx Corporation-Andrx Group ADRX 2  NASDAQ
Advanced Medical Optics, Inc. AVO 0.222222 NYSE
Biovail Corporation BVF 4  NYSE
Bristol-Myers Squibb Company BMY 18  NYSE
Eli Lilly & Company LLY 10  NYSE
Forest Laboratories, Inc. FRX 4  NYSE
Hospira, Inc. HSP 1.4  NYSE
IVAX Corporation IVX 1.875  AMEX
Johnson & Johnson JNJ 26  NYSE
King Pharmaceuticals, Inc. KG 4.25  NYSE
Medco Health Solutions MHS 2.6532 NYSE
Merck & Co., Inc. MRK 22  NYSE
Mylan Laboratories, Inc. MYL 2.25  NYSE
Pfizer Inc. PFE 58  NYSE
Schering-Plough Corporation SGP 14  NYSE
Valeant Pharmaceuticals VRX 1  NYSE
Watson Pharmaceuticals, Inc. WPI 1  NYSE
Wyeth WYE 12  NYSE
Zimmer Holdings, Inc. ZMH 1.8  NYSE

_________________

(1) As of May 6, 2004, as a result of the spin-off of Hospira, Inc. from Abbott Laboratories, Hospira, Inc. will be included in Pharmaceutical HOLDRS. As of May 6, 2004, 1.4 shares of Hospira, Inc. will be included in each round-lot of 100 Pharmaceutical HOLDRS.
   
   

        The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is June 30, 2004.

GRAPHIC 2 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`2`!(``#__@`<4V]F='=A'_W0`$`"C_V@`,`P$``A$#$0`_`/OZ(B1"(B1"(B1" M(B1"(B1"(B1"(B1"(B1"(B1"(B1"(B1"(B1"(B1"(B1"(IC2%=55CZ\5,\DN MQS-N\YQZW]%GLU`2U*B.+9^!F6I461G_`,_1.WD]'V_=Y^S M]WGCWI?J!3MR/,0.\55&S=CT&>TIT1>"KN#HZJ.BI&":J=AS@3]F)GZSC^0\ M3\5I`)Y2DD#G/15UD5%"))=QW.#&M:,N_5`?NW-8^&,LYX(`!QX69`<#P?C_,*AEE9#$^61P:Q@+G./``Y43I":2[7B\WGKV=3 M,UD8(Q]EHZ?PPKE_56Q8H;VI.<>'48^:Y-?U-K%#I2Q'\3<^B"':U@!E>BF]/W^HJZI]N MN#-M4P'#L8SCD$>:I%OT^H34)O3E,UM35-M:$4GJ6JK6WRAI*6KD@$X:T[3T MR78RN[N*^?CTGR/]5F.N8V,E=9;;P/+_`&9:-,`@9G`S[RF11%1/>;%>*6.> MN=413$#J>CAD`C!X5NK=-JA>67:5*\P9"Z@U`'.0818>JKC46ZU-?3/V222! MFX<@8)Z?)9,5JU/-"R5MT;M>T.&97<'X*N[7;+34B%B.)Q^9.O3;DWLP`/66 M2*29:-4QR-?WG&[:K MLUN'//+O:BV`DC)F<\#.U?.+';*Z MXR5?H=::;8X;L.<-V/#'>9OU9OGXT_P#U'KQVJEGHM;QP5,YGE:TYD))S MF,GQ5VL+N6H^MG>O:1=AC&W)W>IM\L)/"65ZQF5UL(Y' MT]9Z;_>&6:VF;HZ>0B."//5[ST'RY^"66C]$I,/>99WG?/,X8=(\\_`<#R`4 M1](=RDI-46H\QTS!.&CDDO.?]H579M1VBHH&2&XTS">6R2!I'3R*^C:IEJ4@ MB)&]C>,9Z;CX^Y*]*[#@FOJ34,FI+@-/6=P-. M]V*BHQD$`]<>P>?C^=G9K9%;+=#2PMQ'&W#<^)Y)^)_-9NF=,T]FILL&Y[^K MWGUG>2I`,#`&`HW6*0$3RCY_,E36P)=_,?C\21=_F.S]G_K*KU,W*PW.:_.N M5#4P1.P`TOSD?9P>F"/-.[]5?BM-^Z/[%P-/9;IVL!K8Y8D8QR/\SKVJEH0A MP,*!QS_4ID67::>[0&7O.KBG!QV>P8QSGP'L6HNI4Y=0Q!'X/.877:V`<^TD M-#<7#]IG_)5ZCZ+3M^MQD]#KZ:(2'+N3G''+?:N^6U:HF86/NT(!_5):?F&Y M7)T-MNGTZU-4Q(STQS)ZS?J:Z[;2XL&#[]/:>/LG?&88'@;A@8ZY/0>/O5ZI5NF:ZWW3TFTU43(^+?Z.'ACVN#V./&>/R)66RS:AC8UC+RP-:,`;>!\EL76GN$\+.[JMM/*T] M=S00X?(X61W?JK\5IOW1_8HZJM#<6\-R>JG&?D3VAV%>-ZXZ$?\`)__0^F75 ME_M%&*J2["1H>&[6CS^"JZ&H-5;Z>H<,&6-KR/+(RIJKL6H;A"(*NXTSXMP) M&,?DT*GI*<4E'!3AQ<(F-8"?'`PN5H4L6YCA@F!YCGCW,W:ED-:C(+9].GQ. MY$1=6881$2(1$2)+:OT@W48BGBF$57$TM:2.CAS@_P`?FH%^@+Y')M,<)'B6 MOS_)?9R,KCK[%IKU=M:[0>$S6:2JQMQ'&?,;5]',G:-?7/!&?4!Z*]MUFIK= M$UD4;`&\;1A:.#[/DN559<]ARYEM=*5C""<`8&%RB*N60B(D0B(D0B(D3QW: M&KJ+54Q4$HBJGL(B>3C:?>IYMDU/!2&-E[$TICER^3(PX[=@'NP>OAG@JM16 M):5&!*WK#')DC);=6O%>X7"!OI#<1,$A_0$$8(./$9RO)W/K=M.UK+K!VG9= MFXNE<7;@=O0XVM]V5@[2!TX/J>\CY[7J^5U2YMR@C9/('B-CR# M$T.]5KBT\CQ]GM7ZI[/J,5<,E1\E*6@U7%EU16P3;JADY:V0MVM!.Z,'' MJD852PN,;2]H:\CJT'(!]Z_2*#OOYB31-G(PB(H2<(B)$(B)$(B)$(B)$(B) >$(B)$(B)$(B)$(B)$(B)$(B)$(B)$(B)$(B)$__9 ` end -----END PRIVACY-ENHANCED MESSAGE-----